The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
CoV Pandemic Response
The purpose of this special notice is to obtain information via White Papers from both MCDC members and other interested industry/academia partners in response to the novel Coronavirus (2019-nCoV) pandemic in the United States (U.S.). The Government is requesting White Papers with a focus on the following areas:
- Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, and achieving Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) within the next one to four (1-4) months.
- Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening. Any technology that can enhance the understanding of disease progression in COVID-19 infected patients is also of interest, including physiologic monitoring and other vital signs indicators, portable technology that enhances patient care in non-hospital settings, and technology that improves sample collection.
Note: Offerors can consider pursuing Assay and/or Device development efforts that could be used for health surveillance, medical diagnostics, or potentially both. Medical diagnostics efforts need to ensure that they meet required regulatory pathways.
- Information systems and technology the Government can use in a handheld Point-of-Care device to collect, screen, collate, report, and monitor disease infection and pandemic spread on a micro and macro level.
- Therapeutics: Drugs and/or drug/device combinations, or platforms currently under development demonstrating efficacy in post-exposure, pre- and post-symptomatic studies for any CoV strain, and capable of achieving EUA from the FDA within the next three (3) months for this ongoing SARS-CoV-2 pandemic. Antibody technologies, accelerating the discovery, development, manufacturing, and prediction of success for these technologies, can also be considered.
- Prophylactics: Drugs or vaccines currently under development demonstrating pre-exposure in vivo efficacy or in vitro activity against any or all strains of CoV. Antibody technology, accelerating the discovery, development, manufacturing and prediction of success for these technologies can be considered.
- Clinical Trials: Opportunities to expeditiously conduct clinical trials for any technology that will require evaluation for FDA approval, will be considered.
This request is Market Research to determine the capability of the industrial base to respond to the 2019-nCoV pandemic. At this time, funding has not been identified for any prototype projects under this request.
Entities are encouraged to provide innovative products and technologies that in the short term (1-6 months), can be rapidly deployed to combat the current pandemic. Long-term solutions (6 months and beyond) are not requested at this time.
Deadline: May 31, 2020
For this request, submission is open to all entities of the US Defense Industrial Base, not just MCDC members. Should a non-MCDC member be selected for award, that entity would be required to join the MCDC prior to award execution.